Anita F. Das, PhD

Cidara Therapeutics

Disclosure(s): No financial relationships to disclose

Poster(s):

• 231 - Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET